Interim Report January-June 2025

About this update from Xvivo Perfusion Ab

GOTHENBURG, SE / ACCESS Newswire / July 11, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) A quarter showing a mixed picture Second quarter 2025 (Apr-Jun)• Net sales amounted to SEK 178.3 million (210.3), corresponding to negative growth of -15 percent in SEK and -9 percent in local currencies. Organic growth amounted to -11 percent in local currencies.• The business area Abdominal delivered sales growth of 19 percent in local currencies. Thoracic and Services returned negative growth: Thoracic -19 percent and Services -1 percent.• Total gross margin was 74 percent (75). The gross margin for the business areas amounted to: Thoracic 86 percent (85), Abdominal 68 percent (63) and Services 34 percent (40).• Operating income (EBIT) amounted to SEK 7.1 million (33.4). Adjusted EBIT amounted to SEK 6.8 million (33.4).• Operating income before depreciation and amortization (EBITDA) amounted to SEK 23.6 million (51.1), corresponding to an EBITDA margin of 13 percent (24). Adjusted EBITDA totaled SEK 23.3 million (51.1), corresponding to an adjusted EBITDA margin of 13 percent (24).• Net profit amounted to SEK 1.6 million (27.2), impacted by currency effects in cash and cash equivalents of SEK -10.9 million (-3.2). Earnings per share amounted to SEK 0.05 (0.86).• Cash flow from operating activities was SEK 8.8 million (24.7). Total cash flow amounted to SEK 18.0 million (-27.2) and was, in addition to operating cash flow, impacted by investments in R&D projects of SEK -36.3 million and the use of a credit facility of SEK 84.6 million to finance increased working capital. Significant events in the quarter• XVIVO presents convincing 12-month follow-up results from the heart trial, NIHP2019• XVIVO wins the SACC-USA Business Award 2025 The period 2025 (Jan-Jun)• Net sales increased to SEK 396.9 million (396.4), corresponding to growth of 0 percent in SEK and 3 percent in local currencies. Organic growth amounted to 1 percent in local currencies.• The business area Abdominal delivered sales growth of 23 percent in local currencies. Thoracic and Services returned negative growth: Thoracic -3 percent and Services -3 percent.• Total gross margin was 74 percent (74). The gross margin for the business areas amounted to: Thoracic 84 percent (83), Abdominal 65 percent (65) and Services 36 percent (38).• Operating income (EBIT) amounted to SEK 33.6 million (52.4)...

View stock analysis, news, and events for Xvivo Perfusion Ab